Luis G. Paz-Ares, MD, PhD, on NSCLC: Results of the PACIFIC Trial

2017 ESMO Congress
Tweet this page

Luis G. Paz-Ares, MD, PhD, of Hospital Universitario 12 De Octubre, discusses phase III study findings on durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable non–small cell lung cancer (Abstract LBA1).

Advertisement

Advertisement



Advertisement